These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31273857)

  • 1. Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients.
    Xiong Z; Cheng M; Zhu P; Huang S; Guo J; Zhang W; Zhou H; Shu Y; Li Q
    Hum Psychopharmacol; 2019 Jul; 34(4):e2699. PubMed ID: 31273857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
    Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
    Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland.
    Ingimarsson O; MacCabe JH; Haraldsson M; Jónsdóttir H; Sigurdsson E
    Nord J Psychiatry; 2017 Oct; 71(7):496-502. PubMed ID: 28632422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
    Melkersson K; Berinder K; Hulting AL
    Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INSIG2 polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine.
    Koskinen S; Kampman O; Solismaa A; Lyytikäinen LP; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Mononen N; Lehtimäki T; Leinonen E
    Pharmacogenomics; 2016 Dec; 17(18):1987-1997. PubMed ID: 27885961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment-resistant schizophrenia: Neutropenia with olanzapine and clozapine, and stabilization with two depot antipsychotics].
    Alba P
    Vertex; 2017 Mar; 28(132):141-144. PubMed ID: 29522636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemia and atypical antipsychotic drugs.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 18():27-35. PubMed ID: 15600382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy.
    Huang TL; Lu CY
    Chang Gung Med J; 2007; 30(1):26-32. PubMed ID: 17477026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
    Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
    J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin.
    Lu ML; Wang TN; Lin TY; Shao WC; Chang SH; Chou JY; Ho YF; Liao YT; Chen VC
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():47-50. PubMed ID: 25496829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders.
    Kraal AZ; Ward KM; Ellingrod VL
    Psychopharmacol Bull; 2017 May; 47(2):8-21. PubMed ID: 28626268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
    Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
    Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does switching to another antipsychotic in patients with clozapine-associated granulocytopenia solve the problem? Case series of 18 patients.
    Coşar B; Taner ME; Eser HY; Altınöz AE; Tarhan R
    J Clin Psychopharmacol; 2011 Apr; 31(2):169-73. PubMed ID: 21346615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
    Ono S; Sugai T; Suzuki Y; Yamazaki M; Shimoda K; Mori T; Ozeki Y; Matsuda H; Sugawara N; Yasui-Furukori N; Okamoto K; Sagae T; Someya T
    BMC Psychiatry; 2018 Jun; 18(1):180. PubMed ID: 29879941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.
    Melkersson KI; Dahl ML
    Psychopharmacology (Berl); 2003 Nov; 170(2):157-66. PubMed ID: 12851739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study.
    Shen H; Wu D; Wang S; Zhao M; Sun W; Zhu X; Zhang N; Yao H; Cui Q; Xiao H
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):756-765. PubMed ID: 29938908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.
    Lin Y; Peng Y; He S; Xu J; Shi Y; Su Y; Zhu C; Zhang X; Zhou R; Cui D
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):71-78. PubMed ID: 29410009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.